Xeris Biopharma Holdings Inc (XERS)
3.225
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 16:00
3.23
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Enterprise Value: 634.18M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 634.18M |
| October 31, 2024 | 632.69M |
| October 30, 2024 | 634.18M |
| October 29, 2024 | 634.18M |
| October 28, 2024 | 634.18M |
| October 25, 2024 | 629.71M |
| October 24, 2024 | 635.67M |
| October 23, 2024 | 616.30M |
| October 22, 2024 | 602.89M |
| October 21, 2024 | 604.38M |
| October 18, 2024 | 608.85M |
| October 17, 2024 | 605.87M |
| October 16, 2024 | 605.87M |
| October 15, 2024 | 602.89M |
| October 14, 2024 | 595.44M |
| October 11, 2024 | 586.50M |
| October 10, 2024 | 567.13M |
| October 09, 2024 | 571.60M |
| October 08, 2024 | 590.97M |
| October 07, 2024 | 589.48M |
| October 04, 2024 | 596.93M |
| October 03, 2024 | 596.93M |
| October 02, 2024 | 586.50M |
| October 01, 2024 | 568.62M |
| September 30, 2024 | 577.56M |
| Date | Value |
|---|---|
| September 27, 2024 | 580.54M |
| September 26, 2024 | 574.58M |
| September 25, 2024 | 570.11M |
| September 24, 2024 | 573.09M |
| September 23, 2024 | 564.15M |
| September 20, 2024 | 589.48M |
| September 19, 2024 | 593.95M |
| September 18, 2024 | 585.01M |
| September 17, 2024 | 585.01M |
| September 16, 2024 | 582.03M |
| September 13, 2024 | 582.03M |
| September 12, 2024 | 579.05M |
| September 11, 2024 | 579.05M |
| September 10, 2024 | 556.70M |
| September 09, 2024 | 550.74M |
| September 06, 2024 | 526.90M |
| September 05, 2024 | 529.88M |
| September 04, 2024 | 546.27M |
| September 03, 2024 | 538.82M |
| August 30, 2024 | 571.60M |
| August 29, 2024 | 570.11M |
| August 28, 2024 | 568.62M |
| August 27, 2024 | 582.03M |
| August 26, 2024 | 585.01M |
| August 23, 2024 | 582.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
20.14M
Minimum
Apr 02 2020
635.67M
Maximum
Oct 24 2024
292.88M
Average
255.96M
Median
Enterprise Value Benchmarks
| Zoetis Inc | 87.42B |
| Zevra Therapeutics Inc | 451.06M |
| NovaBay Pharmaceuticals Inc | 3.615M |
| Palatin Technologies Inc | 13.93M |
| iBio Inc | 9.837M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.00M |
| Revenue (Quarterly) | 48.06M |
| Total Expenses (Quarterly) | 56.25M |
| EPS Diluted (Quarterly) | -0.10 |
| Gross Profit Margin (Quarterly) | 83.79% |
| Profit Margin (Quarterly) | -31.22% |
| Earnings Yield | -13.02% |
| Normalized Earnings Yield | -13.30 |